1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D6D32397D1EF209E0025876C004E851C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/D6D32397D1EF209E0025876C004E851C?OpenDocument
18
19OpenDocument
2018.97.9.172
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Product Launch Excellence

Document Excerpt: Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine: Using Science to Defuse Hostility and Working with Pricing Opposition Groups

DB Image

Excerpt in Cart

ID: MD-801


Features:

27 Info Graphics

60+ Metrics

25 Narratives


Pages/Slides: 4


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5701 “Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine: Using Science to Defuse Hostility and Working with Pricing Opposition Groups”.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Bayer; Boehringer Ingelheim; Eli Lilly and Company; Gilead Sciences; GlaxoSmithKline ; Johnson & Johnson; Merck; Pfizer; Roche; Sprout Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.